Clinical Trial Update: TID 1000 mg Mesalazine Versus TID 2x500 mg Mesalazine in Active Ulcerative Colitis (UC) [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing 1000 mg Mesalazine once daily versus two 500 mg doses taken three times daily in active ulcerative colitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Active Ulcerative Colitis

Drugs mentioned

• Mesalazine (mesalazine)

Snippet

Sponsor: Dr. Falk Pharma GmbH | Conditions: Active Ulcerative Colitis | Phase 3 | Status: COMPLETED